Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

NCT06991114 is registered in ClinicalTrials.gov with Artiva Biotherapeutics, Inc. as lead sponsor.

NCT NCT06991114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06991114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases
Lead sponsor
Artiva Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 9, 2025
Completion date
January 31, 2029
Enrollment
90 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies (iims), iim, myositis, refractory rheumatoid arthritis (ra), rheumatoid arthritis (ra, scleroderma, sjogren syndrome, sjogrens disease, systemic sclerosis (ssc)